In a winning streak for the Swiss giant, Novartis, which announced impressive Phase III results for its AMD drug candidate, RTH258, just earlier this week now has another feather up its cap with the company’s anti-inflammatory drug, Canakinumab, scoring impressively in a 10,000-plus patient Phase III trial for cardiovascular disease.
Interleukin 1 beta or IL-1ß is a key cytokine in the inflammatory pathway that is known to drive the progression of inflammatory atherosclerosis. Canakinumab, was able to significantly reduce the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in patients with a heart attack history and inflammatory atherosclerosis by inhibiting this IL-1ß pyrogen.
Thereby the drug satisfactorily meets its endpoint in one of the largest and longest-running
Phase III trials in the company’s history.
Canakinumab involves a completely different mechanism as compared to the existing drugs that are administered after a heart attack, such as cholesterol-lowering statins or blood-thinners. Therefore the drug is believed to be of high potentially and has all the qualities to on top of standard medicines.
With this amount of success, Novartis without a doubt has taken a huge step in the cardiovascular field and post this achievement and partially because of which, the company’s stocks
have climbed by 2.82% this morning.In a winning streak for the Swiss giant, Novartis, which announced impressive Phase III results for its AMD drug candidate, RTH258, just earlier this week now has another feather up its cap with the company’s anti-inflammatory drug, Canakinumab, scoring impressively in a 10,000-plus patient Phase III trial for cardiovascular disease.Interleukin 1 beta or IL-1ß is a key cytokine in the inflammatory pathway that is known to drive the progression of inflammatory atherosclerosis. Canakinumab, was able to significantly reduce the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in patients with a heart attack history and inflammatory atherosclerosis by inhibiting this IL-1ß pyrogen.
Thereby the drug satisfactorily meets its endpoint in one of the largest and longest-running Phase III trials in the company’s history.
Canakinumab involves a completely different mechanism as compared to the existing drugs that are administered after a heart attack, such as cholesterol-lowering statins or blood-thinners. Therefore the drug is believed to be of high potentially and has all the qualities to on top of standard medicines.
With this amount of success, Novartis without a doubt has taken a huge step in the cardiovascular field and post this achievement and partially because of which, the company’s stocks have climbed by 2.82% this morning.
